Showing results (141-150 of 196) with videos related to
Sort By:
Pageof 20
Journal of Ovarian Research|May 23, 2016
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patientsChiara Mignogna, Nicoletta Staropoli, Cirino Botta, et al.Cancer Biology & Therapy|April 29, 2011
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patientsPierpaolo Correale, Cirino Botta, Assunta Basile, et al.International Journal of Molecular Sciences|September 23, 2022
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple MyelomaKatia Grillone, Caterina Riillo, Roberta Rocca, et al.Oncoimmunology|May 4, 2016
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patientsPierpaolo Correale, Cirino Botta, Elodia Claudio Martino, et al.Molecular and Clinical Oncology|July 11, 2019
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumabRocco Giannicola, Graziella D'Arrigo, Cirino Botta, et al.Cancers|March 29, 2023
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone SarcomasNicoletta Polerà, Antonia Mancuso, Caterina Riillo, et al.Frontiers in Bioengineering and Biotechnology|March 3, 2020
Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell GrowthsTania Limongi, Elisabetta Dattola, Cirino Botta, et al.Journal of Translational Medicine|May 4, 2023
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancerCaterina Riillo, Nicoletta Polerà, Maria Teresa Di Martino, et al.Plos One|March 4, 2014
In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myelomaMaria Teresa Di Martino, Virginia Campani, Gabriella Misso, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2015
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma CellsAnnamaria Gullà, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, et al.Pageof 20